FDA Review Back on Track – Corcept Resubmits Relacorilant for Cushing’s Treatment
Corcept will resubmit its NDA for relacorilant to treat Cushing’s syndrome after positive FDA feedback.
/ 9 items
#CORT↓
UBS Turns Bullish on CORT: Lifyorli Expected to Beat Expectations
UBS upgraded CORT to Buy, raised target to $72 on strong Lifyorli cancer drug outlook and steady Korlym sales. Upside ~60–70%.
FDA Greenlights Relacorilant + Nab-Paclitaxel for Hard-to-Treat Ovarian Cancer
The FDA has approved Corcept's relacorilant (Lifyorli) in combination with nab-paclitaxel for platinum-resistant ovarian, fallopian tube, or peritoneal cancer, showing improved survival by several months.
Corcept Director Drops $3.35 Million on 100,000 Shares – Strong Insider Buy Signal
Corcept Therapeutics director Leonard Baker Jr. purchased 100,000 common shares at ~$33 each in open-market buys.
Corcept Therapeutics Stock Drops After Losing Patent Appeal to Teva
Corcept Therapeutics shares fell sharply to $29.71 in morning trading, following a Federal Circuit ruling affirming no patent infringement by Teva's generic version of Korlym.
FDA Contradicts Corcept: Agency Says It Warned Biotech About Drug Rejection Risk
FDA reveals it warned Corcept Therapeutics multiple times about relacorilant's approval issues before the company submitted its Cushing's syndrome drug application.